WNT5A in tumor development and progression: A comprehensive review - 18/10/22
, Sara Teresinha Olalla Saad, Fernanda Marconi Roversi ⁎ 
Abstract |
The investigation of tumor microenvironment (TME) is essential to better characterize the complex cellular crosstalk and to identify important immunological phenotypes and biomarkers. The niche is a crucial contributor to neoplasm initiation, maintenance and progression. Therefore, a deeper analysis of tumor surroundings could improve cancer diagnosis, prognosis and assertive treatment. Thus, the WNT family exerts a critical action in tumorigenesis of different types of neoplasms due to dysregulations in the TME. WNT5A, an evolutionary WNT member, is involved in several cellular and physiopathological processes, in addition to tissue homeostasis. The WNT5A protein exerts paradoxical effects while acting as both an oncogene or tumor suppressor by regulating several non-canonical signaling pathways, and consequently interfering in cell growth, cytoskeletal remodeling, migration and invasiveness. This review focuses on a thorough characterization of the role of WNT5A in neoplastic transformation and progression, which may help to understand the prognostic potentiality of WNT5A and its features as a therapeutic target in several cancers. Additionally, we herein summarized novel findings on the mechanisms by which WNT5A might favor tumorigenesis or suppression of cancer progression and discussed the recently developed treatment strategies using WNT5A as a protagonist.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | The WNT family is implicated in different types of neoplasms. |
• | WNT5A displays important features that may be of interest to the field of oncology. |
• | WNT5A plays an important role in regulating the tumor microenvironment. |
• | WNT5a act as a tumor suppressor or oncogene dependent onto neoplasm type. |
• | The opposing functions of WNT5a require further understanding. |
Keywords : WNT5A, Tumor suppressor, Oncogene, Tumor microenvironment, Prognostic factor, Target therapy
Plan
Vol 155
Article 113599- novembre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
